Medicare Coverage Expands to Include In-Home IVIG Treatment for Neurological Conditions

The "Medicare IVIG Access Enhancement Act of 2025" is pretty straightforward: It expands Medicare coverage for intravenous immune globulin (IVIG) administration at home, specifically for folks dealing with chronic inflammatory demyelinating polyneuropathy (CIDP) or multifocal motor neuropathy (MMN). (SEC. 2)

Bringing Treatment Home

Right now, Medicare covers in-home IVIG for primary immune deficiency diseases. This bill adds CIDP and MMN to that list. If you're not familiar, IVIG therapy involves getting antibodies through an IV to help your immune system. CIDP and MMN are neurological disorders that can cause weakness and numbness, and IVIG can be a key treatment.

• Real-World Impact: Imagine a retired teacher with CIDP who struggles to get to the hospital regularly. This change means they can potentially receive their treatment without leaving home, saving them time, stress, and potentially money on transportation.

The Cost Factor

The bill also mentions that payment amounts for the in-home IVIG administration can vary depending on whether it's for primary immune deficiency, CIDP, or MMN. (SEC. 2) It will be important to watch how those payment structures are set, to ensure that the cost of providing this service is properly accounted for.

• Potential Challenge: While expanding access is great, it’s important to ensure that home healthcare providers are properly reimbursed, so that they will be able to offer this service. If the payment amounts are too low, it could create a new problem.

Bottom Line

This is a targeted bill that could make a real difference for people living with specific, challenging neurological conditions. It represents a shift toward more patient-centered care by bringing treatment directly to where many patients are most comfortable: their own homes. It also fits in with the existing Medicare coverage for in-home IVIG, simply expanding it to include more conditions.